NCT lookup

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening.
* Is taking at least 1 background therapy (1 immunosuppressant or dapsone and/or 1 antimalarial and/or oral corticosteroids) for SLE.
* Has positive antinuclear antibody (+ANA; titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Smith (anti-Sm) antibody, or positive anti-Sjögren's Syndrome A (SSA)/Ro antibody.
* Has the presence of at least 1 of the following manifestations of SLE: active lupus rash with Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) erythema and scale/hypertrophy combined score \>2, or \>2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs).
* Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a concurrent clinically significant disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
* Has symptomatic heart failure (New York Heart Association Class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening.
* Has a severe chronic pulmonary disease requiring oxygen therapy.
* Has a transplanted organ which requires continued immunosuppression.
* Has a known systemic hypersensitivity to interleukin-2 (IL-2), or modified IL-2 including MK-6194, or its inactive ingredients.
* Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
* Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent.
* Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes.
* Has a diagnosis of antiphospholipid syndrome (APS) with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening.
* Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
* Has an active or clinically significant infection requiring hospitalization or treatment with anti-infectives.
* Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
* Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.
* Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study.
* Is taking more than 1 immunosuppressant.
* Is taking more than 1 oral nonsteroidal anti-inflammatory drug (NSAID), excluding low-dose aspirin (\<350 mg/day), or is taking daily oral NSAID at greater than the maximum recommended dosage.
* Is currently on any chronic systemic (oral or intravenous \[IV\]) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).

• Covina, California, United States
• La Jolla, California, United States
• La Palma, California, United States
• Tujunga, California, United States
• Denver, Colorado, United States
• Clearwater, Florida, United States
• Plantation, Florida, United States
• Tampa, Florida, United States
• Atlanta, Georgia, United States
• Lake Charles, Louisiana, United States
• Grand Blanc, Michigan, United States
• Charlotte, North Carolina, United States
• Charlotte, North Carolina, United States
• Oklahoma City, Oklahoma, United States
• Memphis, Tennessee, United States
• Baytown, Texas, United States
• DeSoto, Texas, United States
• Houston, Texas, United States
• Mesquite, Texas, United States
• Mar del Plata, Buenos Aires, Argentina
• Rosario, Santa Fe Province, Argentina
• Santa Fe, Santa Fe Province, Argentina
• SAN M. de Tucuman, Tucumán Province, Argentina
• Mendoza, Argentina
• Cuiabá, Mato Grosso, Brazil
• Porto Alegre, Rio Grande do Sul, Brazil
• Porto Alegre, Rio Grande do Sul, Brazil
• São Bernardo do Campo, São Paulo, Brazil
• São José do Rio Preto, São Paulo, Brazil
• Sherbrooke, Quebec, Canada
• + 97 more on CT.gov